Late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease
- PDF / 741,283 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 189 Views
ORIGINAL ARTICLE
Late lumen enlargement after drug‑coated balloon angioplasty for de novo coronary artery disease Takayuki Onishi1 · Yuko Onishi1 · Isshi Kobayashi1 · Yasuhiro Sato1 Received: 17 April 2020 / Accepted: 2 July 2020 © Japanese Association of Cardiovascular Intervention and Therapeutics 2020
Abstract We aimed to identify predictors of late lumen enlargement (LLE) after drug-coated balloon (DCB) angioplasty for de novo coronary lesions. LLE, which is defined as an increase in the luminal diameter of the vessel from the immediate postprocedural measurement to follow-up measurements, is frequently observed after DCB angioplasty for de novo coronary artery disease. No predictors of LLE are known. This retrospective observational study analyzed 196 de novo coronary lesions in 182 patients who underwent both DCB angioplasty and follow-up angiography. Of the 196 lesions, 109 (56%) developed LLE during a mean follow-up period of 7.2 ± 2.5 months. As defined by American College of Cardiology (ACC)/American Heart Association (AHA) lesion types, lesions with LLE were significantly less severe than lesions without LLE (types A, B1, B2 and C 15%, 35%, 38% and 13% vs. 7%, 24%, 45% and 24%, respectively; p = 0.036), although no significant differences in clinical or other lesion background characteristics were observed between the groups. Among type C lesions, chronic total occlusion (CTO) was more frequently observed in lesions with LLE than in lesions without LLE (79% vs 43%, p = 0.036). Lesion severity predicts LLE after DCB angioplasty for de novo coronary artery disease. Among type C lesions, CTO is expected in lesions showing LLE, and preparations should therefore be made prior to DCB application. Further research is needed. Keywords Drug-coated balloon · Coronary artery disease · Late lumen enlargement
Introduction Late lumen enlargement (LLE) is a unique feature of drugcoated balloon (DCB) angioplasty for de novo coronary lesions [1]. Without a metallic cage in the vessel wall, DCB-treated lesions can develop an enlarged lumen in the chronic phase, although this condition is rarely observed in stent-treated lesions, in which the implanted stent controls the maximum luminal diameter and restricts dynamic vessel motion. Previous studies that investigated angiographic outcomes after DCB angioplasty have consistently shown that LLE occurs in 48–69% of these cases [2–5]. However, no Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12928-020-00690-2) contains supplementary material, which is available to authorized users. * Takayuki Onishi [email protected] 1
Department of Cardiology, Hiratsuka Kyosai Hospital, 9‑11 Oiwake, Hiratsuka, Kanagawa, Japan
predictors of LLE after DCB angioplasty have been identified. The ability to obtain predictors of this event will help us confidently select lesions suitable for DCB angioplasty and determine procedural endpoints by enabling the preparation for LLE in these lesions at the time of DCB angioplasty. Here
Data Loading...
